Should You Buy Madrigal Pharmaceuticals Inc (MDGL) Stock on Thursday?

Madrigal Pharmaceuticals Inc (MDGL) stock is up 6.69% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Madrigal Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on MDGL!

See Full MDGL Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With MDGL Stock Today?

Madrigal Pharmaceuticals Inc (MDGL) stock is higher by 2.97% while the S&P 500 is lower by -0.18% as of 12:03 PM on Thursday, Nov 30. MDGL has gained $5.86 from the previous closing price of $197.36 on volume of 132,549 shares. Over the past year the S&P 500 is up 14.77% while MDGL has gained 195.33%. MDGL lost -$19.24 per share in the over the last 12 months.

More About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. Click Here to get the full Stock Report for Madrigal Pharmaceuticals Inc stock.